Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169011 | 0.87 | CES2 (0.30) | CES2CES1 | |
| SCHEMBL7933326 | 0.79 | AOC3 (0.47) | ESR1ESR2 | |
| SCHEMBL23237367 | 0.79 | AOC3 (0.47) | ESR1ESR2 | |
| SCHEMBL11076883 | 0.78 | ESR1 (0.36) | CES2CES1ESR1ESR2 | |
| SCHEMBL23236870 | 0.75 | CES2 (0.42) | CES2CES1ESR1ESR2ADRB1 | |
| SCHEMBL27765351 | 0.75 | PNMT (0.41) | CES2 | |
| SCHEMBL1722221 | 0.73 | AR (0.38) | — | |
| SCHEMBL28919999 | 0.73 | CES2 (0.43) | CES2CES1CA12CA1CA9 | |
| SCHEMBL7147434 | 0.71 | APEX1 (0.47) | CES2CES1ADRB1 | |
| SCHEMBL9558453 | 0.71 | TSHR (0.48) | CES2CES1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136336-B2 | Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-10-05 | — | — | US | disclosed |
| WO-2021074196-A1 | THIENOPYRIMIDONES AS TRPA1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-22 | — | — | WO | disclosed |
| US-20210107918-A1 | Novel Thienopyrimidones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107918-A1 | Novel Thienopyrimidones | TRPA1, TRPV1, TRPV2 | CES2 3773/4885CES1 2763/4885CA12 4832/4885 |
| US-11136336-B2 | Thienopyrimidones | TRPA1, TRPV1, TRPV2 | CES2 3614/4885CES1 2890/4885CA12 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.